

- proliferating cell nuclear antigen (PCNA), estrogen and progesterone receptors in human colorectal carcinogenesis using specialized automated cellular image analysis system. PhD thesis, College of Medicine, Al-Nahrain University, 2011.
10. Weisser MK, Rauhut S, Schoch C, et al. Prognostic impact of RT-PCR-based quantification of Wt1 gene expression during mrd monitoring of acute myeloid leukemia. *Leukemia*. 2005; 19: 1416-23.
 11. Rosenfeld C, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. *Leukemia*. 2003; 17: 1301-12.
 12. Huang J, Jin J, Xu WL. WT1 gene expression in myelodysplastic syndrome and its clinical implication. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2006; 35: 132-5.
 13. Kreuzer KA, Saborowski A, Lupberger J, et al. Fluorescent 5'- exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: Implications for monitoring human leukaemias. *Br J Haematol*. 2001; 114: 313-8.
 14. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumour gene (Wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia*. 2001; 9: 1060-7.
 15. Karakas T, Miething CC, Maurer U, et al. The coexpression of the apoptosis-related genes BCL-2 and WT1 in predicting survival in adult acute myeloid leukemia. *Leukemia*. 2002; 16: 846-54.
 16. Gu WY, Chen ZX, Cao XS, et al. Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR. *Zhonghua Xue Ye Xue Za Zhi*. 2004; 25: 728-31.
 17. Cao XS, Gu WY, Chen ZX, et al. Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia. *Zhonghua Nei Ke Za Zhi*. 2007; 46: 277-9.
 18. Aguayo A, Kantarjian H, Manshour T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. *Blood*. 2000; 96: 2240-2245.
 19. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (Sti571) therapy. *Blood*. 2004; 103: 3549-51.
 20. Wagner KD, Wagner N, Wellmann S, et al. Oxygen-regulated expression of the Wilms' tumour suppressor WT1 involves hypoxia-inducible factor-1 (HIF-1). *FASEB J*. 2003; 17:1364-1366.
 21. Trka J, Hrusak O, Zuna J, et al. Real time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. *Leukemia*. 2002; 16: 1381-9.
 22. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of MRD in AML. *Blood*. 1994; 84: 3071-9.
 23. Inoue K, Yamagami T, Soma T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumour gene) expression levels. *Blood*. 1996; 88: 2267-78.
 24. Bergmann L, Maurer U, Brieger J, et al. High levels of Wilms' tumour gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long term outcome. *Blood*. 1997; 90: 1217-25.
 25. Gaiger A, Schmid D, Heinze G, et al. Detection of the Wt1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. *Leukemia*. 1998; 12: 1886-94.
 26. Schmid D, Linnerth B. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. *Leukemia*. 1997; 11: 639-43.

Correspondence to Dr. Mustpha A. Mukeef

E-Mail: drmustafa78@yahoo.com

Received 2nd Oct. 2013; Accepted 27th Oct. 2013